Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study

Satoshi Yamasaki; Takumi Matsushima; Mariko Minami; Masanori Kadowaki; Ken Takase; Hiromi Iwasaki

doi:10.1007/s00277-020-04388-6

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study

Satoshi Yamasaki, Takumi Matsushima, Mariko Minami, Masanori Kadowaki, Ken Takase, Hiromi Iwasaki

Internal Medicine

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	209-211
Number of pages	3
Journal	Annals of Hematology
Volume	101
Issue number	1
DOIs	https://doi.org/10.1007/s00277-020-04388-6
Publication status	Published - Jan 2022

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s00277-020-04388-6

Cite this

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study. / Yamasaki, Satoshi; Matsushima, Takumi; Minami, Mariko et al.
In: Annals of Hematology, Vol. 101, No. 1, 01.2022, p. 209-211.

Research output: Contribution to journal › Letter › peer-review

@article{18e65ad6ff1b4e29b4884d4f22216749,

title = "Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study",

author = "Satoshi Yamasaki and Takumi Matsushima and Mariko Minami and Masanori Kadowaki and Ken Takase and Hiromi Iwasaki",

note = "Funding Information: We thank the patients and clinical staff for their participation in the study. We also acknowledge the Clinical Research Institute, Kyushu Medical Hospital, for editorial support. We thank Joe Barber Jr., PhD, from Edanz Group (https://en-author-services.edanz.com/ac ) for editing a draft of this manuscript.",

year = "2022",

month = jan,

doi = "10.1007/s00277-020-04388-6",

language = "English",

volume = "101",

pages = "209--211",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma

T2 - a single-institute retrospective study

AU - Yamasaki, Satoshi

AU - Matsushima, Takumi

AU - Minami, Mariko

AU - Kadowaki, Masanori

AU - Takase, Ken

AU - Iwasaki, Hiromi

N1 - Funding Information: We thank the patients and clinical staff for their participation in the study. We also acknowledge the Clinical Research Institute, Kyushu Medical Hospital, for editorial support. We thank Joe Barber Jr., PhD, from Edanz Group (https://en-author-services.edanz.com/ac ) for editing a draft of this manuscript.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85098565482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098565482&partnerID=8YFLogxK

U2 - 10.1007/s00277-020-04388-6

DO - 10.1007/s00277-020-04388-6

M3 - Letter

C2 - 33392703

AN - SCOPUS:85098565482

SN - 0939-5555

VL - 101

SP - 209

EP - 211

JO - Annals of Hematology

JF - Annals of Hematology

IS - 1

ER -

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this